The COVID-19 pandemic saw a surge in the use of continuous glucose monitors (CGMs), revolutionizing diabetic care with advanced digital capabilities, resulting in better patient self-management. GlobalData predicts the CGM and insulin pumps market to reach $20.8 billion by 2033.